Literature DB >> 19509544

Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.

Sepideh Farhat1, Mayumi Nakagawa, Anna-Barbara Moscicki.   

Abstract

Cell-mediated immune responses have been thought to be important in the control of human papillomavirus (HPV) infections. We examined cell-mediated immune responses to HPV-16 E6 and E7 in the peripheral blood using interferon gamma (IFN-gamma) enzyme-linked immunospot assay (Cellular Technology Ltd, Cleveland, Ohio) in women with HPV-16 infection who showed clearance and compared these women to women with HPV-16 persistence. Women participating in a longitudinal study of cervical HPV were recruited once cervical HPV-16 infection was detected by polymerase chain reaction. Four groups of women were examined: (1) persistent, (2) intermittent, (3) transient, and (4) cleared. Ninety-six samples from 55 women were compared. Comparing IFN-gamma enzyme-linked immunospot to the HPV-16 clearance of 10 women with recent persistence, none had response to either E6 or E7; of 24 women with recent clearance, 14 had E6 and 8 had E7 response. Women with intermittent persistence behaved similarly to the clearance group than recent persistors: 50% were positive to E6 and 20% to E7. In summary, anti-E6 responses seem critical in the immediate control of HPV, and in some women, an immune tolerance eventually develops if HPV is not eliminated soon after infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509544      PMCID: PMC2766534          DOI: 10.1111/IGC.0b013e3181a388c4

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  22 in total

1.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

Authors:  A B Moscicki; N Hills; S Shiboski; K Powell; N Jay; E Hanson; S Miller; L Clayton; S Farhat; J Broering; T Darragh; J Palefsky
Journal:  JAMA       Date:  2001-06-20       Impact factor: 56.272

2.  Detection of papillomavirus DNA in human semen.

Authors:  R S Ostrow; K R Zachow; M Niimura; T Okagaki; S Muller; M Bender; A J Faras
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

Review 3.  HPV innate immunity.

Authors:  Craig D Woodworth
Journal:  Front Biosci       Date:  2002-10-01

4.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

5.  Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia.

Authors:  Emma J Davidson; Peter Sehr; Rebecca L Faulkner; Joanna L Parish; Kevin Gaston; Richard A Moore; Michael Pawlita; Henry C Kitchener; Peter L Stern
Journal:  J Gen Virol       Date:  2003-08       Impact factor: 3.891

6.  Characterization of IgA response among women with incident HPV 16 infection.

Authors:  Takashi Onda; Joseph J Carter; Laura A Koutsky; James P Hughes; Shu-Kuang Lee; Jane Kuypers; Nancy Kiviat; Denise A Galloway
Journal:  Virology       Date:  2003-07-20       Impact factor: 3.616

7.  Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.

Authors:  Raphael P Viscidi; Linda Ahdieh-Grant; Barbara Clayman; Kelly Fox; Leslie S Massad; Susan Cu-Uvin; Keerti V Shah; Kathryn M Anastos; Kathleen E Squires; Ann Duerr; Denise J Jamieson; Robert D Burk; Robert S Klein; Howard Minkoff; Joel Palefsky; Howard Strickler; Paula Schuman; Eva Piessens; Paolo Miotti
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

8.  Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.

Authors:  Marij J P Welters; Annemieke de Jong; Susan J F van den Eeden; Jeanette M van der Hulst; Kitty M C Kwappenberg; Sabrin Hassane; Kees L M C Franken; Jan Wouter Drijfhout; Gert Jan Fleuren; Gemma Kenter; Cornelis J M Melief; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

9.  Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones.

Authors:  I Kraus; T Molden; L E Ernø; H Skomedal; F Karlsen; B Hagmar
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

10.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.

Authors:  S S Wang; M Schiffman; T S Shields; R Herrero; A Hildesheim; M C Bratti; M E Sherman; A C Rodriguez; P E Castle; J Morales; M Alfaro; T Wright; S Chen; B Clayman; R D Burk; R P Viscidi
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  31 in total

1.  Association between toll-like receptor expression and human papillomavirus type 16 persistence.

Authors:  Ibrahim I Daud; Mark E Scott; Yifei Ma; Stephen Shiboski; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 2.  Human papillomavirus disease and vaccines in adolescents.

Authors:  Anna-Barbara Moscicki
Journal:  Adolesc Med State Art Rev       Date:  2010-08

3.  The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection.

Authors:  Luis F Barroso
Journal:  Ther Adv Vaccines       Date:  2013-07

4.  Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.

Authors:  Cunbao Liu; Xiaojie Chu; Pengyan Sun; Xuejun Feng; Weiwei Huang; Hongxian Liu; Yanbing Ma
Journal:  Hum Vaccin Immunother       Date:  2018-01-23       Impact factor: 3.452

5.  Expression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated response.

Authors:  Mark E Scott; Yifei Ma; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2014-10-30       Impact factor: 7.396

6.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors:  Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

7.  A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot.

Authors:  Hannah N Coleman; Xuelian Wang; William W Greenfield; Mayumi Nakagawa
Journal:  MOJ Immunol       Date:  2014

8.  Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.

Authors:  S Daayana; E Elkord; U Winters; M Pawlita; R Roden; P L Stern; H C Kitchener
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

9.  Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Julie Jay; Evelyn Hanson; Susanna Benningfield; Janet Jonte; Cheryl Godwin-Medina; Robert Wilson; Stephen Shiboski
Journal:  Clin Infect Dis       Date:  2013-12-23       Impact factor: 9.079

10.  Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Teresa M Darragh; Michael Pawlita; Denise A Galloway; Stephen Shiboski
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.